Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ana Rodriguez Regal"'
Autor:
María del Campo Amigo-Jorrín, Luis Anibarro-García, Ana María Lopez Real, Ana Rodriguez-Regal, Laura Ramos-Rúa
Publikováno v:
Patient preference and adherence
Ana Rodríguez-Regal,1 Laura Ramos-Rúa,2 Luis Anibarro-García,3 Ana María Lopez Real,4 María del Campo Amigo-Jorrín1 1Department of Neurology, Complejo Hospitalario Universitario de Pontevedra (CHUP), Pontevedra, Spain; 2Department of Neurology,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b9620208b63b2c874249ab4c7eebd41
https://doi.org/10.2147/ppa.s284425
https://doi.org/10.2147/ppa.s284425
Autor:
José E. Meca-Lallana, José M. Prieto González, Ana B. Caminero Rodríguez, Javier Olascoaga Urtaza, Ana M. Alonso, Eduardo Durán Ferreras, Raúl Espinosa, Julio Dotor, Mercedes Romera, Adrián Ares Luque, Domingo Pérez Ruiz, Carmen Calles, Miguel A. Hernández, Miguel Hervás García, Amelia Mendoza Rodríguez, Yasmina Berdei Montero, Nieves Téllez, Nicolás Herrera Varó, Javier Sotoca, Silvia Presas-Rodríguez, Luis A. Querol Gutierrez, Mariona Hervás Pujol, Jordi Batlle Nadal, Gisela Martín Ozaeta, Laura Gubieras Lillo, Sergio Martínez Yélamos, Lluís Ramió-Torrentà, Javier Mallada Frechin, Antonio Belenguer Benavides, Francisco Gascón-Giménez, Bonaventura Casanova, Lamberto Landete Pascual, Leticia Berenguer, Laura Navarro, Montserrat Gómez Gutierrez, Carmen Durán, Ana Rodríguez Regal, Elena Álvarez, Daniel A. García-Estévez, Ana M. López Real, Miguel A. Llaneza González, María E. Marzo Sola, José L. Sánchez-Menoyo, Agustín Oterino, Ramón Villaverde González, Tamara Castillo-Triviño, Amaya Álvarez de Arcaya, Cristina Llarena
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 2177-2193 (2023)
Abstract Introduction Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing–remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinic
Externí odkaz:
https://doaj.org/article/0d5e12714aa14ddbb6e6eadf49cbbed1
Autor:
Tania García Sobrino, Manuela Lema Bouzas, Ana Rodriguez Regal, Clara Domínguez Vivero, Eva Costa Arpín, José María Prieto González, María del Campo Amigo Jorrín
Publikováno v:
Neurodegenerative disease management. 6(1)
Aim: To evaluate the effect of natalizumab on progression of brain atrophy in multiple sclerosis (MS) patients and to search for a clinical or radiological marker of progression of brain atrophy. Patients and methods: We retrospectively recorded demo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77f3299a061e7d0a83ebfcb61c47554d
https://pubmed.ncbi.nlm.nih.gov/26782312
https://pubmed.ncbi.nlm.nih.gov/26782312
Autor:
Xiana, Rodriguez-Osorio, Francisco J, Lopez-Gonzalez, Antonio, Pato-Pato, Ernesto, Cebrian-Perez, José, Marey-Lopez, Enrique, Corredera-Garcia, Eduardo, Rubio-Nazabal, M Dolores, Castro-Vilanova, Javier, Abella-Corral, Ana, Rodriguez-Regal, M Campo, Amigo-Jorrin, Robustiano, Pego-Reigosa
Publikováno v:
Revista de neurologia. 61(12)
Lacosamide is a sodium channel blocker antiepileptic drug authorized as an adjunctive therapy for focal seizures in adolescents and adults.To analyze the efficacy and safety of lacosamide in Galicia according to its use in daily clinical practice.Ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d7391a9ab5f3546d0d623687bb61c527
https://pubmed.ncbi.nlm.nih.gov/26662871
https://pubmed.ncbi.nlm.nih.gov/26662871
Autor:
M.L. Aguado-Valcárcel, Ana Rodriguez-Regal, Llaneza-González, D. Escriche-Jaime, Alfredo Puy-Núñez, J.R. Lorenzo-González, D.A. García-Estévez, M.J. Moreno-Carretero, M.C. Amigo-Jorrín, Eva Costa-Arpin, M. Rodríguez-Rodríguez, A. López-Real, J.M. Prieto, D. Muñoz, Luciana Midaglia, Pato-Pato A
Publikováno v:
Revista de Neurología. 63:13
Introduction. The effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS) have been proven in clinical trials. Yet,due to their limitations,it is important to know how it behaves under everyday clinical p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0130cceb5bd713500e596d001fc1b4a
https://doi.org/10.33588/rn.63s01.2016255
https://doi.org/10.33588/rn.63s01.2016255
Autor:
Ana Rodriguez-Regal, Javier Abella-Corral, Enrique Corredera-Garcia, Xiana Rodríguez-Osorio, M. Dolores Castro-Vilanova, Robustiano Pego-Reigosa, M Campo Amigo-Jorrin, Eduardo Rubio-Nazabal, Ernesto Cebrian-Perez, en representación del grupo de estudio Galaco, Pato-Pato A, José Marey-Lopez, Francisco Javier López-González
Publikováno v:
Revista de Neurología. 61:536
Introduccion. La lacosamida es un farmaco antiepileptico bloqueante de los canales de sodio, autorizado en adolescentes y adultos como tratamiento coadyuvante en crisis de inicio focal. Objetivo. Analizar los resultados de eficacia y seguridad de la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e93f3ac479943e8268524e75c9404b53
https://doi.org/10.33588/rn.6112.2015359
https://doi.org/10.33588/rn.6112.2015359
Autor:
Ana Paula Suarez-Gil, Iria Cabo-López, María del Campo Amigo, Miguel A Mouriño-Sestelo, Ana Rodriguez Regal, Alfredo Puy-Núñez, Beatrice Canneti
Publikováno v:
Revista de Neurología. 60:381
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0261e36e1f4484b7e171814ca9ed847
https://doi.org/10.33588/rn.6008.2014505
https://doi.org/10.33588/rn.6008.2014505